Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited.

Rate this post
Related Articles

Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited.

Eur J Neurol. 2018 Apr 10;:

Authors: Constantinescu CS, Gershkovich P

Abstract
Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ9 – tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs. This article is protected by copyright. All rights reserved.

PMID: 29633480 [PubMed – as supplied by publisher]


Source: Estudios sobre Cannabidiol (CBD)

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

*

Translate »